Evercore ISI analyst Josh Schimmer downgraded Dice Therapeutics (DICE) to In Line from Outperform after Eli Lilly (LLY) agreed to acquire the company for $48 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DICE:
- Dice Therapeutics downgraded to Hold from Buy at Canaccord
- Dice Therapeutics price target raised to $48 from $38 at Wells Fargo
- DICE Surges after $2.4 Billion Acquisition by LLY
- Eli Lilly to acquire Dice Therapeutics for $48 per share in cash
- Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology